{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T10:14:36Z","timestamp":1787998476547,"version":"build-2784847793"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["R01HS025984"],"award-info":[{"award-number":["R01HS025984"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s40264-022-01200-4","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T11:04:59Z","timestamp":1657796699000},"page":"863-871","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A Disproportionality Analysis of Drug\u2013Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3821-4595","authenticated-orcid":false,"given":"Lorenzo","family":"Villa-Zapata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3916-0402","authenticated-orcid":false,"given":"Ainhoa","family":"G\u00f3mez-Lumbreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4525-4250","authenticated-orcid":false,"given":"John","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malinda S.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2993-2085","authenticated-orcid":false,"given":"Richard D.","family":"Boyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5006-9394","authenticated-orcid":false,"given":"Daniel C.","family":"Malone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,14]]},"reference":[{"key":"1200_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2344\/0003-3006-62.1.31","volume":"62","author":"JA Giovannitti","year":"2015","unstructured":"Giovannitti JA, Thoms SM, Crawford JJ. Alpha-2 adrenergic receptor agonists: a review of current clinical applications. Anesth Prog. 2015;62:31\u20138.","journal-title":"Anesth Prog"},{"issue":"4 Suppl 1","key":"1200_CR2","first-page":"142","volume":"50","author":"J Peck","year":"2020","unstructured":"Peck J, Urits I, Crane J, McNally A, Noor N, Patel M, et al. Oral muscle relaxants for the treatment of chronic pain associated with cerebral palsy. Psychopharmacol Bull. 2020;50(4 Suppl 1):142\u201362.","journal-title":"Psychopharmacol Bull"},{"key":"1200_CR3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1191\/1352458502ms795rr","volume":"8","author":"S Paisley","year":"2002","unstructured":"Paisley S, Beard S, Hunn A, et al. Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review. Mult Scler. 2002;8:319\u201329.","journal-title":"Mult Scler"},{"key":"1200_CR4","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1517\/14656566.9.12.2209","volume":"9","author":"G Malanga","year":"2008","unstructured":"Malanga G, Reiter RD, Garay E. Update on tizanidine for muscle spasticity and emerging indications. Expert Opin Pharmacother. 2008;9:2209\u201315.","journal-title":"Expert Opin Pharmacother"},{"key":"1200_CR5","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1054\/jpai.2000.9435","volume":"1","author":"MR Semenchuk","year":"2000","unstructured":"Semenchuk MR, Sherman S. Effectiveness of tizanidine in neuropathic pain: an open-label study. J Pain. 2000;1:285\u201392.","journal-title":"J Pain"},{"key":"1200_CR6","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.annemergmed.2019.02.017","volume":"74","author":"BW Friedman","year":"2019","unstructured":"Friedman BW, Irizarry E, Solorzano C, Zias E, Pearlman S, Wollowitz A, et al. A randomized, placebo-controlled trial of ibuprofen plus metaxalone, tizanidine, or baclofen for acute low back pain. Ann Emerg Med. 2019;74:512\u201320.","journal-title":"Ann Emerg Med"},{"key":"1200_CR7","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.jpainsymman.2020.06.014","volume":"60","author":"I Garc\u00eda-L\u00f3pez","year":"2020","unstructured":"Garc\u00eda-L\u00f3pez I, Cuervas-Mons Vendrell M, Mart\u00edn Romero I, de Noriega I, Bened\u00ed Gonz\u00e1lez J, Martino-Alba R. Off-label and unlicensed drugs in pediatric palliative care: a prospective observational study. J Pain Symptom Manag. 2020;60:923\u201332.","journal-title":"J Pain Symptom Manag"},{"key":"1200_CR8","unstructured":"US FDA. ZANAFLEX\u00ae (tizanidine hydrochloride) tablets. 2013. p. 9. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/021447s011_020397s026lbl.pdf. Accessed 21 Jan 2022."},{"key":"1200_CR9","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1081\/CLT-200026978","volume":"42","author":"HA Spiller","year":"2004","unstructured":"Spiller HA, Bosse GM, Adamson LA. Retrospective review of tizanidine (Zanaflex\u00ae) overdose. J Toxicol Clin Toxicol. 2004;42:593\u20136.","journal-title":"J Toxicol Clin Toxicol"},{"key":"1200_CR10","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1136\/jnnp.57.11.1355","volume":"57","author":"M Emre","year":"1994","unstructured":"Emre M, Leslie GC, Muir C, Part NJ, Pokorny R, Roberts RC. Correlations between dose, plasma concentrations, and antispastic action of tizanidine (SirdaludTM). J Neurol Neurosurg Psychiatry. 1994;57:1355\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1200_CR11","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2165\/00003495-199753030-00007","volume":"53","author":"AJ Wagstaff","year":"1997","unstructured":"Wagstaff AJ, Bryson HM. Tizanidine. Drugs. 1997;53:435\u201352.","journal-title":"Drugs"},{"key":"1200_CR12","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s40262-016-0371-x","volume":"55","author":"L Gabriel","year":"2016","unstructured":"Gabriel L, Tod M, Goutelle S. Quantitative prediction of drug interactions caused by CYP1A2 inhibitors and inducers. Clin Pharmacokinet. 2016;55:977\u201390.","journal-title":"Clin Pharmacokinet"},{"key":"1200_CR13","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1046\/j.1365-2125.2003.02028.x","volume":"57","author":"MT Granfors","year":"2004","unstructured":"Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro. Br J Clin Pharmacol. 2004;57:349\u201353.","journal-title":"Br J Clin Pharmacol"},{"key":"1200_CR14","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.clpt.2005.06.009","volume":"78","author":"MT Granfors","year":"2005","unstructured":"Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Clin Pharmacol Ther. 2005;78:400\u201311.","journal-title":"Clin Pharmacol Ther"},{"key":"1200_CR15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.clpt.2003.12.005","volume":"75","author":"MT Granfors","year":"2004","unstructured":"Granfors MT, Backman JT, Neuvonen M, Ahonen JNP. Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. Clin Pharmacol Ther. 2004;75:331\u201341.","journal-title":"Clin Pharmacol Ther"},{"key":"1200_CR16","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.clpt.2004.08.018","volume":"76","author":"MT Granfors","year":"2004","unstructured":"Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clin Pharmacol Ther. 2004;76:598\u2013606.","journal-title":"Clin Pharmacol Ther"},{"key":"1200_CR17","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.clpt.2004.08.003","volume":"76","author":"K Momo","year":"2004","unstructured":"Momo K, Doki K, Hosono H, Homma MKY. Drug interaction of tizanidine and fluvoxamine. Clin Pharmacol Ther. 2004;76:509\u201310.","journal-title":"Clin Pharmacol Ther"},{"key":"1200_CR18","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1177\/0091270009341961","volume":"50","author":"K Momo","year":"2010","unstructured":"Momo K, Homma M, Osaka Y, Inomata SI, Tanaka M, Kohda Y. Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics. J Clin Pharmacol. 2010;50:331\u20137.","journal-title":"J Clin Pharmacol"},{"key":"1200_CR19","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/cpdd.788","volume":"9","author":"W Zhang","year":"2020","unstructured":"Zhang W, McIntyre C, Riehl T, Forbes H, Bertran E, Choi HJ, et al. Effect of vemurafenib on the pharmacokinetics of a single dose of tizanidine (a CYP1A2 Substrate) in patients with BRAF V600 mutation-positive malignancies. Clin Pharmacol Drug Dev. 2020;9:651\u20138.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1200_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00228-007-0389-y","volume":"64","author":"JT Backman","year":"2008","unstructured":"Backman JT, Schr\u00f6der MT, Neuvonen PJ. Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine. Eur J Clin Pharmacol. 2008;64:17\u201324.","journal-title":"Eur J Clin Pharmacol"},{"key":"1200_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/7909703","volume":"2020","author":"A Belayneh","year":"2020","unstructured":"Belayneh A, Molla F. The effect of coffee on pharmacokinetic properties of drugs: a review. Biomed Res Int. 2020;2020:1\u201311.","journal-title":"Biomed Res Int"},{"key":"1200_CR22","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.clpt.2006.08.017","volume":"80","author":"K Momo","year":"2006","unstructured":"Momo K, Homma M, Kohda Y, Ohkoshi N, Yoshizawa TTA. Drug interaction of tizanidine and ciprofloxacin: case report. Clin Pharmacol Ther. 2006;80:717\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"1200_CR23","doi-asserted-by":"publisher","unstructured":"Toxicity of Tizanidine (Zanaflex) Exacerbated by coadministration of ciprofloxacin: a case report and literature review. J Hosp Med. 2012;7:1. https:\/\/doi.org\/10.1002\/jhm.1927","DOI":"10.1002\/jhm.1927"},{"key":"1200_CR24","first-page":"157","volume":"15","author":"LI Montesinos-Magraner","year":"2013","unstructured":"Montesinos-Magraner LI, Gas\u00f3-Gago I, Ram\u00edrez-Garcer\u00e1n L, Lalueza-Broto MP, Ju\u00e1rez-Gonz\u00e1lez JC, Girona-Brum\u00f3s L. Alucinaciones visuales y auditivas secundarias a la interacci\u00f3n farmacol\u00f3gica entre tizanidina y ciprofloxacino. Pharm Care Espana. 2013;15:157\u20139.","journal-title":"Pharm Care Espana."},{"issue":"8","key":"1200_CR25","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.jclinane.2015.05.016","volume":"27","author":"A Abd-Elsayed","year":"2015","unstructured":"Abd-Elsayed A, Elsharkawy H, Sakr W. A severe interaction between tizanidine and ciprofloxacin. J Clin Anesth. 2015;27(8):698.","journal-title":"J Clin Anesth"},{"key":"1200_CR26","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/cpt.1233","volume":"105","author":"S Chaugai","year":"2019","unstructured":"Chaugai S, Dickson AL, Shuey MM, Feng Q, Barker KA, Wei W, et al. Co-prescription of strong CYP1A2 inhibitors and the risk of tizanidine-associated hypotension: a retrospective cohort study. Clin Pharmacol Ther. 2019;105:703\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"1200_CR27","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s00228-020-02981-2","volume":"77","author":"A Rudolph","year":"2021","unstructured":"Rudolph A, Dahmke H, Kupferschmidt H, Burden A, Weiler S. Coadministration of tizanidine and ciprofloxacin: a retrospective analysis of the WHO pharmacovigilance database. Eur J Clin Pharmacol. 2021;77:895\u2013902.","journal-title":"Eur J Clin Pharmacol"},{"key":"1200_CR28","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/1060028018775914","volume":"52","author":"AM J\u00f6dicke","year":"2018","unstructured":"J\u00f6dicke AM, Curkovic I, Zellweger U, Tomka IT, Neuer T, Kullak-Ublick GA, et al. Analysis of drug-drug interactions in swiss claims data using tizanidine and ciprofloxacin as a prototypical contraindicated combination. Ann Pharmacother. 2018;52:983\u201391.","journal-title":"Ann Pharmacother"},{"key":"1200_CR29","first-page":"275","volume":"133","author":"K Momo","year":"2013","unstructured":"Momo K, Homma M, Matsumoto S, Sasaki T, Kohda Y. Clinical survey of tizanidine-induced adverse effects\u2014impact of concomitant drugs providing cytochrome P450 1A2 modification. Pharm Sci J. 2013;133:275\u201381.","journal-title":"Pharm Sci J"},{"key":"1200_CR30","unstructured":"FDA Adverse Events Reporting System (FAERS) [cited 2021 Feb 1]. https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files. Accessed 6 Feb 2022."},{"key":"1200_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2016.26","volume":"3","author":"JM Banda","year":"2016","unstructured":"Banda JM, Evans L, Vanguri RS, Tatonetti NP, Ryan PB, Shah NH. A curated and standardized adverse drug event resource to accelerate drug safety research. Sci Data. 2016;3: 160026.","journal-title":"Sci Data."},{"key":"1200_CR32","unstructured":"Flockhart DA, Thacker D, McDonald C, Desta Z. The Flockhart cytochrome P450 drug\u2013drug interaction TableTM. Division of Clinical Pharmacology, Indiana University School of Medice; 2021. https:\/\/drug-interactions.medicine.iu.edu\/MainTable.aspx. Accessed 11 Nov 2021."},{"key":"1200_CR33","doi-asserted-by":"crossref","unstructured":"Hansten PD, Horn JR. The top 100 drug interactions: a guide to patient management, 2010 edition. 21st ed. H&H Publications; 2021.","DOI":"10.1345\/aph.1P108"},{"key":"1200_CR34","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1345\/aph.1H423","volume":"41","author":"JR Horn","year":"2007","unstructured":"Horn JR, Hansten PD, Chan L-N. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007;41:674\u201380.","journal-title":"Ann Pharmacother"},{"key":"1200_CR35","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"J-L Montastruc","year":"2011","unstructured":"Montastruc J-L, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72:905\u20138.","journal-title":"Br J Clin Pharmacol"},{"key":"1200_CR36","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13:519\u201323.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1200_CR37","unstructured":"European Medicines Agency. Screening for adverse reactions in EudraVigilance. Europe; 2016. https:\/\/www.ema.europa.eu\/en\/documents\/other\/screening-adverse-reactions-eudravigilance_en.pdf. Accessed 23 Feb 2021."},{"key":"1200_CR38","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/j.1365-2125.2006.02653.x","volume":"62","author":"JT Backman","year":"2006","unstructured":"Backman JT, Karjalainen MJ, Neuvonen M, Laitila J, Neuvonen PJ. Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. Br J Clin Pharmacol. 2006;62:345\u201357.","journal-title":"Br J Clin Pharmacol"},{"key":"1200_CR39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40264-015-0351-3","volume":"39","author":"M-A Maci\u00e1-Mart\u00ednez","year":"2016","unstructured":"Maci\u00e1-Mart\u00ednez M-A, de Abajo FJ, Roberts G, Slattery J, Thakrar B, Wisniewski AFZ. An empirical approach to explore the relationship between measures of disproportionate reporting and relative risks from analytical studies. Drug Saf. 2016;39:29\u201343. https:\/\/doi.org\/10.1007\/s40264-015-0351-3.","journal-title":"Drug Saf"},{"key":"1200_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.650369","volume":"8","author":"J Yuan","year":"2021","unstructured":"Yuan J, Shen C, Wang C, Shen G, Han B. Assessment of physician\u2019s knowledge of potential drug-drug interactions: an online survey in China. Front Med (Lausanne). 2021;8: 650369.","journal-title":"Front Med (Lausanne)."},{"key":"1200_CR41","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(08)61490-7","volume":"372","author":"JA Baron","year":"2008","unstructured":"Baron JA, Sandler RS, Bresalier RS, Lanas A, Morton DG, Riddell R, et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet. 2008;372:1756\u201364.","journal-title":"Lancet"},{"key":"1200_CR42","doi-asserted-by":"publisher","unstructured":"Sibbald B. Rofecoxib (Vioxx) voluntarily withdrawn from market. Can Med Assoc J. 2004;171:1027\u20138. https:\/\/doi.org\/10.1503\/cmaj.1041606.","DOI":"10.1503\/cmaj.1041606"},{"key":"1200_CR43","doi-asserted-by":"publisher","first-page":"c7086","DOI":"10.1136\/bmj.c7086","volume":"342","author":"S Trelle","year":"2011","unstructured":"Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086. https:\/\/doi.org\/10.1136\/bmj.c7086.","journal-title":"BMJ"},{"key":"1200_CR44","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1093\/jamia\/ocaa034","volume":"27","author":"H Edrees","year":"2020","unstructured":"Edrees H, Amato MG, Wong A, Seger DL, Bates DW. High-priority drug-drug interaction clinical decision support overrides in a newly implemented commercial computerized provider order-entry system: override appropriateness and adverse drug events. J Am Med Inform Assoc. 2020;27:893\u2013900.","journal-title":"J Am Med Inform Assoc"},{"key":"1200_CR45","unstructured":"US FDA label. ACCOLATE\u00ae (zafirlukast). US FDA; 2009. p. 9. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020547s027lbl.pdf. Accessed 5 May 2022."},{"key":"1200_CR46","doi-asserted-by":"publisher","first-page":"C40","DOI":"10.1016\/S0149-2918(98)80007-6","volume":"20","author":"SA Goldman","year":"1998","unstructured":"Goldman SA. Limitations and strengths of spontaneous reports data. Clin Ther. 1998;20:C40\u20134.","journal-title":"Clin Ther"},{"key":"1200_CR47","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1208\/s12248-009-9127-y","volume":"11","author":"S-F Zhou","year":"2009","unstructured":"Zhou S-F, Yang L-P, Zhou Z-W, Liu Y-H, Chan E. Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J. 2009;11:481\u201394.","journal-title":"AAPS J"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01200-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-022-01200-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01200-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T08:40:53Z","timestamp":1665564053000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-022-01200-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,14]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1200"],"URL":"https:\/\/doi.org\/10.1007\/s40264-022-01200-4","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,14]]},"assertion":[{"value":"6 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by the Agency for Healthcare Research and Quality, grant number R01HS025984.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Lorenzo Villa-Zapata, Ainhoa G\u00f3mez-Lumbreras, John Horn, Malinda S. Tan, Richard D. Boyce, and Daniel C. Malone report no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethic approval was not sought from the Institutional Review Board as the study only involved the analysis of data obtained from a public database. Informed consent to participate was not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate\/publication"}},{"value":"The source data for this study are publicly available. Analytical datasets are available from the corresponding author on reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Computer code used in this analysis is available from the authors on request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"LVZ participated in developing the study protocol and research design, analyzed data, and contributed to interpretation the data. AGL has participated developing the study protocol and research design, interpretation of the data and drafted the first manuscript. JH participated in the research protocol, interpretation of the data and edited the manuscript. MT participated in developing the research design and interpretation of the results. RB participated in the study design, conducted the data extraction and data analysis. DCM supervised the study and drafted the study protocol and research design, guided the analysis of the data, provided interpretation as well as edited the manuscript. All authors have reviewed and approved the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contribution"}}]}}